RGNX REGENXBIO Inc.

NASDAQ
$7.40

REGENXBIO Inc. (RGNX) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $1.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -34.4% since its last earnings release on August 6, 2026.

REGENXBIO Beat Consensus Estimates
Thursday, August 6, 2026 · 7:05 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:05 AM ET
Earnings Whisper
-
vs ($1.36)
Rev est $9.6M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.21

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.